Tevogen Bio Holdings Inc (TVGN) USD0.0001 A

Sell:$1.25Buy:$1.27$0.03 (2.33%)

Prices delayed by at least 15 minutes
Sell:$1.25
Buy:$1.27
Change:$0.03 (2.33%)
Prices delayed by at least 15 minutes
Sell:$1.25
Buy:$1.27
Change:$0.03 (2.33%)
Prices delayed by at least 15 minutes

Company Information

About this company

Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The Company is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, has developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic lingering symptoms of the disease. Its TVGN 601 is being developed for multiple sclerosis (MS), and its TVGN 930 is being developed for EBV-associated lymphomas.

Key people

Ryan Saadi
Chairman of the Board, Chief Executive Officer
Kirti Desai
Chief Financial Officer
Neal Flomenberg
Chief Scientific Officer and Global R&D Lead
Sadiq Khan
Chief Commercial Officer
Jeffrey Feike
Independent Director
Keow Lin Goh
Independent Director
Curtis Patton
Independent Director
Susan M. Podlogar
Independent Director
Victor Sordillo
Independent Director
Click to see more

Key facts

  • EPIC
    TVGN
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US88165K1016
  • Market cap
    $237.22m
  • Employees
    18
  • Shares in issue
    183.89m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.